Viatris Sues Novo Nordisk Over Generic Version of Wegovy
Viatris (VTRS) has filed a lawsuit against Novo Nordisk (NVO), seeking permission from a Delaware federal court to market a generic version of the weight loss drug Wegovy. The suit, filed by Mylan—now part of Viatris after its 2020 acquisition—argues that certain patents covering Wegovy are invalid or should not be enforced. Wegovy is one of Novo Nordisk’s top-selling drugs and has been a major driver of the company's recent growth. The legal action could potentially allow Viatris to launch an affordable generic alternative, which may disrupt Novo Nordisk’s market dominance in this segment. The outcome of this case will have significant implications for both companies' revenue streams and competitive positioning within the GLP-1 drug class.
Topics: generic drugs GLP-1 therapy patents pharmaceuticals Wegovy